Study biobank for people newly diagnosed with certain blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new (recent) diagnosis of leukemia or a related blood disorder
- Your condition must be one of: AML, ALL, high-risk MDS, or myelofibrosis related to MPN (specific types)
- You have not had prior treatment for this condition (except certain allowed medicines)
- You agree to join and do not oppose being enrolled in the study cohort
- You have health insurance (social security or other coverage)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how different blood cancers and early (pre-cancer) blood conditions work, using tumor/blood tissue samples. It may help researchers learn more about disease biology for future treatments, with little to no extra risk if samples come from routine care.
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This trial creates a biobank of blood or bone marrow samples from patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or high-risk myelodysplastic syndrome (MDS). It aims to collect samples for future research, which may help develop better treatments.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.